Clinical benefit of pelabresib (Cpi-0610) in combination with ruxolitinib in JAK inhibitor treatment-naive myelofibrosis patients: interim efficacy subgroup analysis from Arm 3 of the MANIFEST Phase 2 Study
Authors
Gupta, V.Kremyanskaya, M.
Mascarenhas, J.
Palandri, F.
Patriarca, A.
Devos, T.
Harrison, C.
Passamonti, F.
Rampal, R.
Mead, A.
Scandura, J.
Hobbs, G.
Talpaz, M.
Granacher, N.
Somervaille, Tim CP
Hoffman, R.
Bose, P.
Colak, G.
Shao, J.
Cui, J. K.
Bobba, S.
Luptakova, K.
Verstovsek, S.
Affiliation
Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, CanadaIssue Date
2021